retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity The power of three: Retatrutide's role in modern and diabetes therapy 🚨 Today, retatrutide, the GIP/GLP-1/glucagon

It is administered once weekly via subcutaneous injection and is being researched in late-stage trials for obesity and type 2 diabetes, but it is not yet approved

GLP-1 agonists produce 5-10 times more weight loss because they create massive caloric deficits through appetite suppression and gastric slowing

Long-Term Maintenance and What Comes After Reaching your goal weight on Retatrutide is a milestone, but the conversation does not end there

Upon reconstitution, the stability of a peptide is contingent upon the type of solvent utilized

Obesity is a stigmatized condition, and people have a lot of judgments about people taking the medications," says Jay

doi: 10.3904/kjim.2020.505 8 AndersenDKKorcMPetersenGMEiblGLiDRickelsMRet al